Data Previously Presented in 2017 at the 13th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) DUBLIN, Ireland , June 19, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel
DUBLIN, Ireland, May 24, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience category, today announced that the Company has initiated a reorganization to align its
Net cash used in operating and investing activities was $31.8 million in the first quarter; quarter-end cash and restricted cash position of $433.1 million supports advancement through key milestones of R&D pipeline Entered into global neuroscience research & development collaboration with Celgene
DUBLIN, Ireland, May 01, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience and orphan categories, will announce financial results for the first quarter of 2018 on
Phase 2b PRONTO study did not meet its primary or secondary endpoints Phase 3 VITAL Amyloidosis Study being discontinued based on futility analysis Investor conference call and webcast today at 8:30 AM ET DUBLIN, Ireland, April 23, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a
Prothena to receive a $100 million upfront payment and a $50 million equity investment by Celgene, with potential license payments and regulatory and commercial milestones, plus additional royalties on net sales from licensed programs Collaboration focuses on preclinical programs targeting proteins
DUBLIN, Ireland, March 12, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced that it will present new
DUBLIN, Ireland, March 07, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced that members of its
Net cash used in operating and investing activities was $39.9 million in the fourth quarter and $134.7 million for the full year 2017; quarter-end cash and restricted cash position of $421.7 million supports advancement through key milestones of R&D pipeline Completed enrollment in the Phase 2b
DUBLIN, Ireland, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced that members of its senior
DUBLIN, Ireland, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that Sarah Noonberg, MD, PhD, has decided to resign
DUBLIN, Ireland, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it will report its fourth quarter and full year
DUBLIN, Ireland, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced that members of its senior
DUBLIN, Ireland, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan arenas, today announced that members of its senior
Clinical development programs advancing toward key milestones Dr. Morie Gertz of Mayo Clinic discusses clinical aspects of AL amyloidosis and the role of cardiac biomarker NT-proBNP Novel discovery pipeline in neuroscience and orphan disease areas; highlights include tau and ALECT2 R&D Day hosted
